Corcept's Q2 2025 saw 60% therapy demand growth despite bottlenecks. Despite near-term operational risks, we maintain long-term bullish estimates on CORT stock. See more.
Corcept's Q2 Demand Grows 60% Penetrating Large Type 2 Diabetes Market Early (NASDAQ:CORT)
Seeking Alpha Stock15 hrs ago
108
Reuters US Business
Odessa American
Reuters US Economy
The Traverse City Record-Eagle
The Motley Fool
Ledger-Enquirer
Daily Meal